Kornimate/medical-research-clean huggingface dataset:
aronia berry consumption on blood pressure

Conditions: Prehypertension; Healthy

Summary: aronia berries are a native north american berry with high naturally occurring anthocyanins among other polyphenols. based on their polyphenol composition, there is growing interest in the potential for aronia berries to elicit health promoting cardio-metabolic effects. specifically, aronia berry extracts, which provide a concentrated source of polyphenols, may improve blood vessel function. thus, the primary focus of this project is to evaluate the effects of aronia berry polyphenols on blood pressure and other biomarkers of cardiovascular disease risk such as endothelial function, arterial stiffness and blood lipids.


Eligibility criteria:
inclusion criteria: * healthy men and women aged 40-70 years old * blood pressure comprised between: sbp 120/139 mmhg or dbp 80/89 mmhg * subjects are willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study * are able to understand the nature of the study * able and willing to give signed written informed consent * signed informed consent form exclusion criteria: * manifest cardiovascular disease including coronary artery disease, cerebrovascular disease and peripheral artery disease * grade 1 hypertensive or above, as defined as sbp superior or equal to 140 mmhg or dbp superior or equal to 90 mmhg * obese participants, defined as bmi superior or equal to 30 * diabetes mellitus and metabolic syndrome * acute inflammation * chronic and acute disease * terminal renal failure and other kidney abnormalities * malignancies * abnormal heart rhythm * allergies to berries or other significant food allergy. * subjects who require treatment for hypertension at any time (e.g. statins, aspirin, blood pressure lowering drugs) * subjects who took food supplements, dietary supplement or herbal remedies within 1 month of study start * subjects who have lost more than 10% of their weight in the past 6 months or are currently in a diet * subjects who reported participant in another study within 1 month before the study start * subjects who smoke an irregular amount of cigarettes per day * subjects who require chronic antimicrobial or antiviral treatment * subjects with unstable psychological condition * subjects with history of cancer, myocardial infarction, cerebrovascular incident * unable to swallow the capsule * pregnant, lactating or planning to become pregnant, as well as premenopausal women who do not have an adequate method of contraception * any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements.

Keywords: (poly)phenols aronia berry blood pressure vascular function
pilot study of anlotinib with stupp regimen for patients with newly diagnosed glioblastoma

Conditions: Glioblastoma

Summary: the purpose of this study is to test the the efficacy and safety of anlotinib in combination with stupp regimen for patients with newly diagnosed glioblastoma.


Eligibility criteria:
inclusion criteria: 1. primary, pathologically confirmed glioblastoma, and complete molecular biological marker tests (mgmt, 1p/19q, idh, tert, braf, p53, egfr); 2. 2 \~ 6 weeks after operation; the surgical incision healed well; 3. presence of lesions evaluable according to rano criteria; 4. aged 18-70 years; 5. karnofsky performance status (kps) ≥ 60; 6. the dose of corticosteroid therapy was stable or gradually reduced in the past 5 days; 7. no previous radiotherapy, chemotherapy, immunotherapy, or biologic therapy; 8. serum hemoglobin ≥ 100 g/l, platelet count ≥ 80 × 109/l, neutrophil count ≥ 1.5 × 109/l; 9. serum creatinine ≤ 1.25 × uln or creatinine clearance ≥ 60 ml/min; 10. serum bilirubin ≤ 1.5 × uln, ast (sgot) and alt (sgpt) ≤ 2.5 × uln, alkaline phosphatase ≤ 5 × uln; 11. normal coagulation function (pt prolongation does not exceed 3s, aptt prolongation does not exceed 10s); 12. women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and be willing to use an appropriate method of contraception during the trial and 8 days after administration of the trial drug. males must agree to use an appropriate method of contraception or be surgically sterile during the trial and after 8 weeks of trial drug administration; 13. patient is sufficiently compliant with study and follow-up procedures; 14. patients signed a formal informed consent form to indicate that they understood that the study was in accordance with hospital policy and ethical requirements. exclusion criteria: 1. secondary glioblastoma; 2. patients with any other malignant tumor before or now, except skin non-melanotic carcinoma or cervical carcinoma in situ; 3. any other diseases or conditions are contraindications to chemoradiotherapy (such as active phase of infection, within 6 months after cerebral myocardial infarction, symptomatic heart disease including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy); 4. pregnant or lactating women; 5. women and men who are likely to become pregnant but are unwilling to take appropriate contraceptive measures; 6. evidence of hereditary bleeding constitution or coagulation disorders; 7. patients requiring anticoagulant therapy due to other diseases;
long-term outcomes after percutaneous closure of pfo

Conditions: Foramen Ovale, Patent; Echocardiography; Embolic Stroke; Atrial Fibrillation

Summary: international medical centre medicor from slovenia has reported 306 successful percutaneous closures of patent foramen ovale (pfo) from october 2006 till june 2022. the investigators are going to follow-up the participants clinically and with contrast transthoracic echocardiography (tte) to define the percentage of functional percutaneous closure. the latter is defined with the number (ten or less) of contrast-bubbles in the left atrium during valsalva maneuver and contrast (agitated saline) application. the clinical follow-up will show the recurrence of embolic events (cerebrovascular insults, transient ischemic attacks) after percutaneous closure. in addition all of the participants are going to be screened for atrial fibrillation. the patients with moderate residual shunts (more than ten bubbles in the left atrium) will then according to the protocol have a transesophageal echocardiogram (tee) to show the eventual mechanism of the shunt. if the tee will not show any signs of a residual shunt, the patients will undergo a computed tomography angiogram (cta) of the pulmonary circulation to exclude arterio-venous fistulas as a cause of the shunt seen on tte. the investigators will also show the comparison in functional closure between classic and alternative device occluders.


Eligibility criteria:
inclusion criteria: * patients who had a neurological event confirmed by a neurologist. * patients who underwent percutaneous closure of pfo in mc medicor (slovenia) from 2006 to 2022. exclusion criteria: * patients who had additional congenital heart defects (as is atrial septal defects). * professional divers, who had the percutaneous closure of pfo because of an episode of decompression sickness.

Keywords: patent foramen ovale transthoracic echocardiography cerebrovascular insult transient ischemic attack atrial fibrillation
swipe out stroke (sos): feasibility of using a consumer based electronic application to improve compliance with weight loss in obese minority stroke patients

Conditions: Stroke

Summary: this pilot study evaluates the use of a mobile application to improve weight loss in obese stroke patients. the investigators hypothesize that acute stroke patients who use the mobile application are more likely to achieve a minimum 5% weight reduction during the critical six months post-stroke, yielding considerable improvement in stroke risk factors.


Eligibility criteria:
inclusion criteria: 1. ischemic or hemorrhagic stroke. 2. age 18-85 years. 3. african-american or hispanic. 4. modified rankin scale (mrs) of 0-3. 5. body mass index greater than 30 kg/m2. 6. currently taking prescription medication for diabetes mellitus, hypertension or hyperlipidemia. 7. willing to follow a healthy eating pattern and not use weight loss medications for the duration of the study. 8. personal ownership or caregiver ownership of a personal computer, smartphone or other smartdevice (iphone or android platform) with internet access. 9. if patient has alexia, agraphia, acalculia, dementia or blindness - caregiver must be willing to complete the intervention. exclusion criteria: 1. pre-existing disability with mrs \> 4. 2. contraindications to weight loss (planning to become pregnant, history of an eating disorder). 3. steroid use for suspected vasculitis. 4. current or recent (past 6 months) participation in a weight loss program or use of weight loss medication.

Keywords: mobile applications
does pulmonary rehabilitation improve frailty?

Conditions: Disease, Pulmonary

Summary: frailty is a state of health with predisposition to adverse events, morbidity and mortality. frailty consists of weakness, slowness, low physical activity, exhaustion, and wasting. frailty is associated with increased hospitalizations and death in lung disease. it is unknown if pulmonary rehabilitation will improve frailty markers.

individuals referred to pulmonary rehabilitation will be examined for frailty markers. after completing pulmonary rehabilitation, the same tests will be performed. the effects of pulmonary rehabilitation will be examined.

Eligibility criteria:
inclusion criteria: * referred for pulmonary rehabilitation * consenting to research exclusion criteria: -under 18 years of age
nstride aps versus hyaluronic acid for knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: this is a two-phase multicenter, double-blind, randomized, prospective evaluation of intra-articular injection(s) comparing aps to intra-articular ha injection(s). the maximum study duration for each subject will be 50 months; 48 months from treatment to last follow-up, and two additional months if the maximum visit window is realized. a total of 246 patients will be enrolled. these patients will meet specific inclusion and exclusion criteria, but can be generally characterized as patients with painful unilateral knee oa who have been unable to achieve satisfactory pain relief with previous conservative oa treatment.


Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age at time of screening. * willingness and ability to comply with study procedures and visit schedules and able to follow oral and written instructions. * a standing knee radiograph showing a k-l grade of 2 to 4 * body mass index ≤ 40 kg/m2 * a qualifying womac lk 3.1 pain subscale total score * signed an ethics committee-reviewed and approved informed consent form. exclusion criteria: * presence of clinically observed active infection in the index knee * presence of symptomatic oa in the non-study knee at screening * diagnosed with rheumatoid arthritis, reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; hiv, viral hepatitis; chondrocalcinosis, paget's disease, or villonodular synovitis * diagnosed with leukemia, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment * presence of venous or lymphatic stasis in the index leg * a history of local anesthetic allergy * previously documented failed treatment with nstride aps or synvisc one

Keywords: autologous protein solution (aps) intra-articular injection osteoarthritis
treatment of laryngotracheal stenosis using mesenchymal stem cells

Conditions: Tracheal Stenosis; Laryngeal Stenosis; Mesenchymal Stem Cells

Summary: the trial evaluates the safety and efficacy of the olfactory mucosa-derived mesenchymal stem cells based therapy for the patients with chronic laryngeal and tracheal stenosis

trial evaluating the safety and efficacy of olfactory mucosa-derived mesenchymal stem cells based therapy for the patients with chronic laryngeal and tracheal stenosis. mesenchymal stem cells are obtained from tissue biopsy of olfactory mucosa using explant method. biomass of autologous mesenchymal stem cells in 10% human albumin solution is injected submucosally around and over the tissue after removal of a granuloma tissue during surgical intervention.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of chronic laryngeal or tracheal stenosis; * absence of cartilage damage. exclusion criteria: * refuse of patient to participate in the trial; * acute infectious diseases; * chronic mental disorders with severe manifestations; * pregnancy/lactation; * intercurrent severe chronic diseases; * hiv, hepatites b/c; * active tuberculosis; * alcohol use disorder/drug addiction; * cachexia of any origin; * malignant neoplasms.

Keywords: mesenchymal stem cells tracheal stenosis laryngeal stenosis cell therapy
different chemotherapy protocols combined with intensity modulated radiation therapy in patients with locally advanced nasopharyngeal carcinoma

Conditions: Drug-Related Side Effects and Adverse Reactions

Summary: this study was to evaluate the efficacy ,toxic reaction and safety of different chemotherapy combined with radiotherapy on patients with locally advanced nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * patients \> 18, \<70 years old, with locally advanced nasopharyngeal carcinoma. exclusion criteria: * patients who had accepted radiotherapy before patients with any ather types of cancer

Keywords: locally advanced nasopharyngeal carcinoma concurrent chemoradiotherapy toxic reaction
cytokine removal in critically ill patients requiring surgical therapy for infective endocarditis (recreate)

Conditions: Endocarditis; Sepsis; Septic Shock

Summary: infectious endocarditis (ie) and other severe infections are well-known to induce significant changes in the immune response including immune functionality in a considerable number of affected patients. in fact, numerous patients with ie develop a persistent functional immunological phenotype that can best be characterized by a profound anti-inflammation and/or functional anergy. this was previously referred to as "injury-associated immunosuppression (iai)" by pfortmüller et al., published in intensive care medicine experimental 2017. iai can be assessed by measurement of cellular (functional) markers. persistence of iai is associated with prolonged icu length of stay, increased secondary infection rates, and death. immunomodulation to reverse iai was shown beneficial in immunostimulatory (randomized controlled) clinical trials. cytosorb® treatment is currently used as standard of care in some institutions in surgically treated ie patients. the investigators aim to investigate two accepted treatment protocols and aim to explore whether adsorption with a cytokine adsorption filter can increase immune competence in treated individuals.


Eligibility criteria:
inclusion criteria: * subjects scheduled for routine cardiac surgery for infectious endocarditis (diagnosed according to the predefined "duke" criteria) with antibiotic therapy for ≤ 14 days. * presence of informed consent * age ≥18 yrs. exclusion criteria: * previous treatment (last 6 months) with immunologically-active biologicals or specific immunomodulatory drugs (e.g. rituximab) * high-dose chronic (i.e. before onset of infectious endocarditis) steroid medication with prednisone equivalent of \>30 mg/d * patients on extracorporeal membrane oxygenation (ecmo), or any other (pre-operative) cardiac assist device * moribund patient (life expectancy \<14 days)
computed tomography evaluation of urinary stones densities compared to in vitro analysis of its chemical composition

Conditions: Urinary Calculi

Summary: the ability to predict stone composition, which influences patient treatment, depends on the accurate measurement of ct attenuation of stones. we will study the effects of stone composition, stone size, and scan collimation width on the measurement of attenuation in vitro.

recently, the use of noncontrast spiral computerized tomography (ncct) has gained widespread acceptance in the evaluation of urinary stone patients. it has long been used clinically to evaluate the causes of radiolucent filling defects using hounsfield units (hu) to distinguish calculi from tumor or blood clots, and to identify nonurologic causes of flank pain (smith r etal ). urinary stones have a significantly higher ct attenuation than the surrounding soft tissues and are virtually always visible on ncct. knowing the composition of a urinary calculus is frequently a key factor in determining its most appropriate management. should the urine be alkalinized? will the stone be amenable to extracorporeal shock wave lithotripsy (eswl), or should ureteroscopy or percutaneous lithotripsy be attempted? different techniques have been used to assist in determining the correct chemical composition of calculi. urine ph, urinary crystals, prior stone history and the presence of urea-splitting organisms (ramakumar s,etal). several in vitro studies have suggested that ncct can demonstrate measured differences in radiodensity among different urinary stones (mitchenson hd etal,).with these clinical problems in mind, we sought to determine whether the composition of urinary calculi could be predicted by their ct characteristics in an attempt to find out the best technique for distinguishing the various stones compositions, provided that it is clinically practical and would not require repeated imaging of the patients.

Eligibility criteria:
inclusion criteria: * any age will be included . * patient with suspected or known urinary stone disease. * eligible for doing ncct. * giving written consent to participate exclusion criteria: * patient with classical ncct contraindication like morbid obesity and pregnancy . * patients with urinary stones will be treated by eswl * refusal participation .
expanded access protocol using hboc-201

Conditions: Anemia

Summary: the purpose of this protocol is to provide treatment with hboc-201 to patients with life-threatening anemia for whom allogeneic blood transfusion is not an option. hboc 201 \[hemoglobin glutamer - 250 (bovine)\] has been previously studied as an alternative to blood transfusions in severely anemic patients needing a way to enhance tissue oxygenation. hboc-201 is purified, cross-linked and polymerized acellular bovine hemoglobin in a modified lactated ringer's solution, and does not require blood compatibility.


Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years of age 2. critically ill patients with hemoglobin ≤ 6 g/dl (or 7-8 g/dl with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits 3. patients or their legally authorized representative who are able and willing to provide informed consent 4. blood is not an option due to: * refusal of transfusion * lack of compatible red blood cells exclusion criteria: 1. patients with known hypersensitivity or allergy to beef products 2. patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis\* 3. patients who are eligible for blood transfusions 4. patients who are \> 80 years old\* * on a case by case and quality of life determination
evaluation of benefit of nebulized bronchodilators at home in severe chronic obstructive pulmonary disease and very severe steady state

Conditions: Severe Chronic Obstructive Pulmonary Disease

Summary: design studies of nebulization in copd does not respond adequately to the clinically relevant question: the intervention of administering nebulized bronchodilators at home it is likely to make a profit, compared to the standard optimized treatment as defined by the recommendations of the splf, patients with severe copd (stage iii, fev between 30% and 50% of the theoretical value) and very severe (stage iv, less than 30% of the theoretical value fev)? the concept of profit in this context is based on criteria of dyspnea, quality of life, use of health system (exacerbations, hospitalizations, prescription of antibiotics and steroids ...).


Eligibility criteria:
inclusion criteria: * adult * copd patients stage 3 et 4 * has not submitted an exacerbation in the 3 months preceding the pre-inclusion visit * weaned from tobacco for at least 6 months * vaccinated against pneumococcal * have not been included in a pulmonary rehabilitation program during the 6 months preceding the screening visit inclusion * patient pre-included not showing exacerbation since the pre-inclusion visit exclusion criteria: * patient under nebulizer or has been treated with nebulized bronchodilators at home over the last 6 months * patient with an indication of oxygen is expected in the coming year * progressive malignant disease known * patient under non-invasive ventilation (niv) for less than 6 months or niv provided in the following year * patient known to be colonized by pseudomonas aeruginosa, a. xylosoxidans, burkholderia cepacia or stenotrophomonas maltophilia * patients with severe cardiovascular disease * pregnancy

Keywords: weaned tobacco has not submitted an exacerbation in the past 3 months
the acute effect of moderate intensity stair-climbing on postprandial blood glucose

Conditions: Postprandial Hyperglycemia

Summary: this study aims to investigate the effect of moderate intensity stair-climbing bouts of various durations on postprandial blood glucose. participants will perform a standard oral glucose tolerance test (ogtt) using 75g of dextrose and with fingerstick blood glucose measurements at baseline and every 15 minutes after consuming the drink for one hour. on separate subsequent visits, participants will perform the same ogtt combined with three stair-climbing bouts lasting 1, 3, and 10 minutes starting 27, 25, and 18 minutes respectively after finishing the drink. participants performed maximal aerobic capacity (vo2max) using a ramp treadmill test in order to assess the relative intensity of each stairclimbing trial.


Eligibility criteria:
inclusion criteria: * defined as low risk per the american college of sports medicine (acsm, guidelines for exercise testing \& exercise prescription, 20014 pg 30) * physical activity recall questionnaire (par-q) screening exclusion criteria: * glucose intolerance * diabetes